An observational study in Type 1 Diabetes, Type 2 Diabetes Treated With Insulin and Hyperglycemia, sponsored by Imperial College Healthcare NHS Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Imperial College Healthcare NHS Trust · Observational
The aim of this observational study is to assess safety and implementation of continuous glucose monitors within the Intensive Care Unit. The Dexcom G7 is a continuous glucose monitoring system that shows blood glucose values in real-time and includes alarms if the glucose is very low or high.
Aim: To assess safety and implementation of networked CGM with ViewsEMR® telemetry within ICU.
The study will be conducted in a two-stage process:
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's planned enrollment of 70 is below the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Imperial College Healthcare NHS Trust is the lead sponsor of 80 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults admitted to the intensive care unit with hyperglycaemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adjunctive use of continuous glucose monitoring (Dexcom G7) with telemetry (ViewsEMR/CampViews®)
Device: Dexcom G7 · Device: ViewsEMR telemetry
Use of continuous glucose monitoring (Dexcom G7) without telemetry (ViewsEMR/CampViews®)
Device: Dexcom G7
Continuous glucose monitoring.
ViewsEMR Telemetry is a digital platform used to monitor participants' real-time CGM data and glucose trends
Phase 1: Eligible participants that consent to participate.
Percentage of eligible participants that consent to participate, including the percentage enrolled through participant informed consent, via personal consultee, and via nominated consultee.
Time frame: Throughout Phase 1 study period, up to 6 months
Phase 1: Time from admission to ICU to initiation of CGM
Time in minutes from admission to ICU to initiation of CGM
Time frame: From admission to ICU to initiation of CGM, up to 48 hours
Phase 1: Time from consent to initiation of CGM
Time from consent to initiation of CGM
Time frame: From enrollment to the end of intervention at 10 days
Phase 1: Percentage of CGM data availability for each participant
Percentage of CGM data availability for each participant
Time frame: From enrollment to the end of intervention at 10 days
Phase 1: Percentage of participants successfully set-up on telemetry (ViewsEMR ®)
Percentage of participants successfully set-up on telemetry (ViewsEMR ®)
Time frame: From enrollment to the end of intervention at 10 days
Phase 1: Number of premature sensor failures per participant (defined as <70% of anticipated use)
Number of premature sensor failures per participant (defined as \<70% of anticipated use)
Time frame: From enrollment to the end of intervention at 10 days
Phase 1: Number and type of adverse events related to CGM use (e.g., skin irritation, device malfunction)
Number and type of adverse events related to CGM use (e.g., skin irritation, device malfunction)
Time frame: From enrollment to the end of intervention at 10 days
Phase 1: Proportion of participants completing the study
Proportion of participants completing the study
Time frame: Throughout Phase 1 study period, up to 6 months
Phase 1: Proportion of nursing staff completing study survey
Proportion of nursing staff completing study survey
Time frame: Throughout Phase 1 study period, up to 6 months
Phase 2: Number of episodes of hypoglycaemia per participant
Number of episodes of hypoglycaemia per participant (defined as \<3.9mmol/L for 15minutes)
Time frame: Throughout Phase 2, up to 30 days
Phase 1: Safety Outcomes
\- Duration of CGM signal loss (units: minutes)
Time frame: From enrollment to the end of intervention, up to 10 days
Plan to share: No — Ethics approval does not allow sharing of individual participant data
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imperial College Healthcare NHS Trust